Abstracts

Abstract submission deadline: 06 March 2025

Click the button below to submit your abstract.

Please note you will need to register for a new Congress website account. This is separate from your EACR membership account and any previous Congress accounts you have had before.

Submit an abstract

---

Sign up to the mailing list for EACR 2025 to receive email reminders about key deadlines.

---

Call for Abstracts

View the EACR 2025 Call for Abstracts (PDF)

This document gives full details on abstract regulations, abstract format, the selection process and how accepted abstracts will be presented, as well as the full list of topics and sub-topics. Accepted EACR 2025 abstracts will be published in an online supplement to the journal Molecular Oncology.

• Abstract selection and presenter registration
• Abstract Topics

---

Abstract selection and presenter registration

The Scientific Committee will make the selection of abstracts for oral and poster presentations by 08 April 2025.  The presenting author will receive an email with the result of the review and the Scientific Committee’s decision on the abstract no later than 08 April 2025. 

The submitting author for each abstract must designate a presenter who agrees to register for the Congress by 28 April 2025 and present in detail the research discussed in the published abstract. 

If the assigned presenter cannot attend the congress, the authors are expected to designate a replacement or withdraw the abstract no later than 28 April 2025. If by 28 April 2025 the presenting author of the abstract is not registered the abstract will be withdrawn from the programme and publication. We strongly advise that presenting authors put funding and/or visa arrangements in place as early as possible after submission to avoid disappointment.

For questions regarding the online submission process, please contact: eacr@newway-management.com

---

Topics for Abstract Submission 

1.    CANCER CELL BIOLOGY
Cell Proliferation / Cell Cycle
Cell Death / Autophagy
Oncogenes and Tumour Suppressor Genes
Metastases and EMT
Ageing and Cancer
Senescence
Cancer Cell Metabolism
Cancer Initiating Cells / Cancer Stem Cells

2.    CANCER GENOMICS
Genomic Alterations in Cancer
Functional Genomics
Genomic profiling of Tumours
Large-scale Approaches to Cancer Gene Discovery
Spatial and 3D Analysis of Tumours
Genomes and Transcriptomes of Cancer at Single Cell Level

3.    EPIGENETICS
DNA Methylation 
Epigenetic changes as Molecular Markers of Cancer 
Epigenomics 
Histone Modification
Epigenetic Mechanisms and Gene Silencing 
Chromatin Structure and Function

4.    BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Application of Bioinformatics to Cancer Biology
Artificial Intelligence and Machine Learning
New Algorithms and new Software for Data Analysis
Mathematical Modeling and Statistical Methods
Molecular Modeling
Database Resources and Network Biology
Omics Technologies
Digital Clinical Trials

5.    TUMOUR EVOLUTION AND HETEROGENEITY
Causes and Consequences of Tumour Heterogeneity
Methods to measure Tumour Evolution and Heterogeneity
Drug Resistance and Clonal Evolution

 
6.    DRUG RESISTANCE 
Novel Mechanisms
Regulation of Gene Expression in Drug Resistance
Reversal of Drug Resistance
Drug Transport and Metabolism
Resistance to Immune Checkpoint Blockade and other Immune based Therapies

7.    BIOMARKERS IN TISSUE AND BLOOD
Liquid Biopsies: Circulating DNA
Liquid Biopsies: Circulating Tumour Cells
Diagnostic Biomarkers
Prognostic Biomarkers
Biomarkers Predictive of Therapeutic Benefit
Early Detection Biomarkers

8.    SIGNALING PATHWAYS
Receptors and Signal Transduction 
Gene Expression, Transcriptional Regulation
Systems Biology
Intracellular Networks
Computational Models of Biological Systems

9.    CARCINOGENESIS
Mutagenesis, Carcinogen Metabolism 
Promotion and Progression 
DNA Damage and Repair
Viral Oncogenesis

10.    TRANSLATIONAL RESEARCH
Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment 
Molecular Pathology 
Imaging 
Clinical Phase I/II trials with Targeted Drugs and Novel Agents
Bioinformatics in Therapies and Clinical Trials
Infrastructures (Biobanks, Databases, Genomic Resources, others)
Nanotechnologies in Cancer Research

11.    EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Drug Discovery / Drug Design
Novel Targets, Delivery Systems 
Mechanisms of Drug Action, Drug Profiling
New Therapies
Pharmacogenetics and Therapeutic Response
Pharmacogenomics
Pharmacokinetics 
Precision Medicine
Target Degradation

12.    TUMOUR IMMUNOLOGY
Tumour Immunology
Immune Suppression and Escape
Tumour Antigens and Immune Effectors
Oncogenic Pathway-mediated Deregulation of Tumour Immunity
Antigen Processing and Presentation
Microbiome and Cancer

13.    IMMUNOTHERAPY    
Adoptive Cell Therapy
Immune Response to Therapies
Immunomodulatory Agents and Interventions
Therapeutic Antibodies, including Engineered Antibodies
Vaccines 
Immune Checkpoints
Immune Mechanisms invoked by other Therapies including CARs

14.    RADIOBIOLOGY / RADIATION ONCOLOGY
Tumour Cell Sensitisation to Radiotherapy
Radiation-activated Signaling Pathways
Cell Cycle and Apoptosis in Radiation Responses
Radiation Oncology; Preclinical and Clinical
Translational Radiation Research

15.    MOLECULAR AND GENETIC EPIDEMIOLOGY
Risk Factors
Risk Assessment
Susceptibility Genes
Genotype / Phenotype Correlations
Genetic Polymorphisms and Cancer Susceptibility
Epidemiology

16.    PREVENTION and EARLY DETECTION
Preclinical Prevention Studies, Markers and Prevention
Clinical Prevention Studies
Vaccination Against Cancer
Risk Factors: Heritable and Lifestyle-related Risk Factors

17.    TUMOUR BIOLOGY 
Animal Models of Cancer 
Genetic and Genomic Instability
Tumour Progression: Invasion and Metastasis
Tumour Microenvironment  
Tumour Angiogenesis
Tumour Inflammation
RNA Biology in Cancer (splicing, noncoding RNAs, RNA modifications) and Therapy Response 
Cell Competition
Tumour Dormancy and Persister Cells
 

---